Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Posted: August 14, 2024 at 2:37 am

– Dose finding ongoing in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML –

Go here to read the rest:
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights

Related Posts